4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
5.04 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 20.723 | 3.129 | 18.038 | 13.612 | 6.986 | 14.13 | 5.79 |
Cost of Revenue
| 97.096 | 3.88 | 3.02 | 53.038 | 38.718 | 18.362 | 13.573 |
Gross Profit
| -76.373 | -0.751 | 15.018 | -39.426 | -31.732 | -4.232 | -7.783 |
Gross Profit Ratio
| -3.685 | -0.24 | 0.833 | -2.896 | -4.542 | -0.3 | -1.344 |
Reseach & Development Expenses
| 97.096 | 80.253 | 61.36 | 53.038 | 38.718 | 18.362 | 13.573 |
General & Administrative Expenses
| 36.494 | 32.908 | 28.011 | 17.238 | 13.895 | 6.167 | 3.489 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 36.494 | 32.908 | 28.011 | 17.238 | 13.895 | 6.167 | 3.489 |
Other Expenses
| 0 | 2.538 | 0.016 | -0.181 | -0.046 | -0.002 | -0.04 |
Operating Expenses
| 133.59 | 113.161 | 89.371 | 70.276 | 52.613 | 24.529 | 17.062 |
Operating Income
| -112.867 | -110.032 | -71.333 | -56.664 | -50.764 | -10.399 | -11.272 |
Operating Income Ratio
| -5.446 | -35.165 | -3.955 | -4.163 | -7.267 | -0.736 | -1.947 |
Total Other Income Expenses Net
| 12.03 | 2.538 | 0.016 | -0.029 | 1.458 | 0.848 | 0.049 |
Income Before Tax
| -100.837 | -107.494 | -71.317 | -56.693 | -49.306 | -9.551 | -11.223 |
Income Before Tax Ratio
| -4.866 | -34.354 | -3.954 | -4.165 | -7.058 | -0.676 | -1.938 |
Income Tax Expense
| 0 | -6.418 | -3.02 | -0.152 | 3.633 | 0.848 | -0.089 |
Net Income
| -100.837 | -101.076 | -68.297 | -56.541 | -52.939 | -9.551 | -11.223 |
Net Income Ratio
| -4.866 | -32.303 | -3.786 | -4.154 | -7.578 | -0.676 | -1.938 |
EPS
| -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
EPS Diluted
| -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
EBITDA
| -107.118 | -106.152 | -68.313 | -55.221 | -44.623 | -9.702 | -10.646 |
EBITDA Ratio
| -5.169 | -35.165 | -3.955 | -4.057 | -5.652 | -0.687 | -1.839 |